Heat Biologics Stock News

28 Feb 2020 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific and Medical Officer, Dr Frédéric Triebel, and Director of Clinical Development and Regulatory Affairs,

By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Full Year 2019 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported first quarter 2020 results in a May 15th release along with

Biotechnology company Immutep (ASX: IMM) has published results from two ongoing clinical studies, just days after revealing it received €2.1 million (A$3.6 million) in research and development tax i

Biomarck Pharmaceuticals, Ltd., a biopharmaceutical company developing targeted anti-MARCKS technology for the treatment of ARDS [Acute Respiratory Di

A trifecta of phase 2 trial results in lung, stomach and colorectal cancer bode well for the blockbuster sales projections for AstraZeneca and Daiichi Sankyo HER2 antibody-drug conjugate Enhertu

DURHAM, NC / ACCESSWIRE / May 29, 2020 / Heat Biologics, Inc. ("Heat") (HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system,

The

As the fallout from the coronavirus pandemic continues, the search for a vaccine is not slowing down.

Bristol-Myers Squibb has won a second first-line lung cancer approval from the FDA for its Opdivo and Yervoy combination.

With the year’s biggest oncology conference days away, Gilead Sciences is signaling now what its cancer immunotherapy pipeline could look like in the